Ziprasidone in parkinsonian dopamine psychosis;Ziprasidona en la psicosis dopaminérgica parkinsoniana

Revista de Neurologia

Volumn 46, Issue 8, 2008, Pages 476-480

  Durán Ferreras, Eduardo ^a,b   Alvarez Lopez M ^a   Garcia Moreno J M ^a   Chacon J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b NONE   (Spain)

Author keywords

Atypical antipsychotics; Dopamine psychosis; Parkinson's disease; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; QUETIAPINE; ZIPRASIDONE;

DOPAMINE PSYCHOSIS; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PARKINSON DISEASE; PATHOLOGICAL LAUGHTER; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 44449134084     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4608.2007378     Document Type: Review

References (61)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely & Jones; 1817.
2. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-45.
3. Kulisevsky J, Martínez-Ramírez S. Tratamiento de la psicosis en la enfermedad de Parkinson. Neurol Supl 2007; 3: 21-6.
4. Fenellon G, Gotees CG, Karenberg A. Hallucinations in Parkinson's disease in the prelevodopa era. Neurology 2006; 66: 93-8.
5. Lang AE, Lozano AM. Parkinson's disease. N Engl J Med 1998; 339: 1130-43.
6. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999; 52 (Suppl 3): S10-3.
7. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-9.
8. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-71.
9. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14: 866-74.
10. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56 (Suppl 5): S1-88.
11. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985; 254: 2792-5.
12. Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998; 59 (Suppl 12): S23-7.
13. Campbell M, Young PI, Bateman DN, Smith JM, Thomas SHL. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol 1999; 47: 13-22.
14. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15: 201-11.
15. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995; 45: 432-4.
16. Idaanpaan-Heikkila J, Alhave E, Okinvora M, Palva I. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 193-8.
17. Durán E, Chacón J, Durán JA. Papel de la olanzapina en la psicosis dopaminérgica parkinsoniana. Rev Neurol 2002; 35: 691-6.
18. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29: 331-7.
19. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months duration. Mov Disord 2007; 22: 313-8.
20. Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 2078-81.
21. Fernández HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27: 4-5.
22. Monografía de Zeldox ®. Madrid: Pfizer; 2003.
23. Connemann BJ, Schoenfeld-Lecuona C. Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry 2004; 49: 73.
24. Shiah IS, Lin CL, Mao WC, Luu SU. Ziprasidone in the treatment of Parkinson's disease psychosis. Eur Psychiatry 2006; 21: 578-9.
25. Oechsner M, Korchounov A. Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol Clin Exp 2005; 20: 203-5.
26. Micheli F, Taubenslag N, Gatto E, Scorticanti MC. Ziprasidone and psychosis in Parkinson's disease. Clin Neuropharmacol 2005; 28: 254.
27. Gómez-Esteban JC, Zarranz JJ, Velasco F, Lezcano E, Lachen MC, Rouco I, et al. Use of zyprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28: 111-4.
28. Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007; 109: 188-91.
29. López del Val LJ, Santos S. Quetiapina y ziprasidona en el tratamiento de los trastornos psicóticos de la enfermedad de Parkinson. Rev Neurol 2004; 39: 661-7.
30. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56: 595-601.
31. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9 (Suppl 3): S417-23.
32. Wolters E. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl 2006; 71: 31-7.
33. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605-10.
34. Baca E, Azanza JR, Giner J, Saiz-Ruiz J, Vallejo J, Díez T, et al. Ziprasidone: from pharmacology to the clinical practice. One year of experience. Actas Esp Psiquiatr 2005; 33: 311-24.
35. Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207-15.
36. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003; 64 (Suppl 12): S2-97.
37. Chacón JR, Durán E, Durán JA, Álvarez M. Utilidad de la olanzapina en la psicosis inducida por levodopa en pacientes parkinsonianos. Neurología 2002; 17: 7-11.
38. Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, et al. Improvement in cognitions associated with novel antipsychotic drugs: a direct drug effect or reduction of extrapyramidal symptoms? Schizophr Res 2000; 46: 81-9.
39. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Arch Gen Psychiatry 2000; 57: 249-58.
40. Purdon SE. Olanzapine and models of cognition. In Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson GD, eds. Olanzapine (Zyprexa): a novel antipsychotic. Baltimore: Williams & Wilkins; 2000.
41. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry 2003; 64 (Suppl 19): S33-9.
42. Kudla D, Lambert M, Domin S, Kasper S, Naber D. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial. Eur Psychiatry 2007; 22: 195-202.
43. Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 (Suppl 1): S70-8.
44. Thome J, Kopf D. Haematological abnormalities during treatment with atypical antipsychotics. Psychiatr Prax 2005; 32: 167-71.
45. Cowan C, Oakley C. Leukopenia and neutropenia induced by quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 292-4.
46. Montgomery J. Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia. Gen Hosp Psychiatry 2006; 28: 83-5.
47. Pessina A, Turlizzi E, Bonomi A, Guizzardi F, Cavicchini L, Croera C, et al. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006; 39: 20-2.
48. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmacol 2004; 19: 205-7.
49. Ozen ME, Yumru M, Savas HA, Cansel N, Herken H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry 2007; 8: 42-4.
50. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004; 26: 1105-8.
51. Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007; 85: 249-56.
52. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 (Suppl 1): S20-7.
53. Meisel A, Winter C, Zschenderlein R, Arnold G. Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Mov Disord 2004; 19: 991-2.
54. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005; 66: 1463-7.
55. De Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95-102.
56. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
57. Montes JM, Rodríguez JL, Balbo E, Sopelana P, Martín E, Soto JA, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 383-8.
58. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003; 17: 423-30.
59. Barnett AA. Safety concerns over the antipsychotic drug sertindole (news item). Lancet 1996; 348: 256.
60. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007; 13: 137-77.
61. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics 2006; 47: 264-8.